SEARCH

SEARCH BY CITATION

References

  • 1
    Lu PW, Briody BJ, Ogle GD et al. Bone mineral density of total body, spine and femoral neck in children and young adults: a cross sectional and longitudinal study. J. Bone Miner. Res. 1994; 9: 14518.
  • 2
    Wark J. Osteoporotic fracture: background and prevention strategies. Maturitas 1996; 23: 193207.
  • 3
    Fleisch H. Bisphosphonates in Bone Disease: From the Laboratory to the Patient, 4th edn. Academic Press, London, 2000.
  • 4
    Rogers MJ, Frith JC, Luckman SP et al. Molecular mechanisms of action of bisphosphonates. Bone 1999; 24 (Suppl.): S7379.
  • 5
    Russell RG, Rogers MJ. Bisphosphonates: from the laboratory to the clinic and back again. Bone 1999; 25: 97106.
  • 6
    Brumsen C, Handy NAT, Papapoulos SE. Long term effects of bisphosphonates on the growing skeleton. Medicine 1997; 76: 26683.
  • 7
    Storm T, Thamsberg G, Steiniche T, Genant HK, Sorensen O. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N. Engl. J. Med. 1990; 322: 126571.
  • 8
    Adachi JD, Benson WA, Brown J. Intermittent cyclical etidronate therapy in the prevention of corticosteroid induced osteoporosis. N. Engl. J. Med. 1997; 337: 3827.
  • 9
    Trombetti A, Arlot M, Thevonen J, Uebelhart B, Meunier PJ. Effect of multiple intravenous courses in Paget's disease of bone. Rev. Rhum. Engl. Ed. 1999; 66: 46776.
  • 10
    Body JJ, Bartl R , Burckhardt P, Delmas P. Current use of bisphophonates in oncology. J. Clin. Oncol. 1998; 16: 389099.
  • 11
    Chappard D, Minaire P, Privat C et al. Effects of tiludronate on bone loss in paraplegic patients. J. Bone Miner. Res. 1995; 10: 11218.
  • 12
    Nance PW, Schrevers O, Leslie W, Ludwig S, Krahn J, ­Uebelhart D. Intravenous pamidronate attenuates bone density loss after acute spinal cord injury. Arch. Phys. Med. Rehabil. 1999; 80: 24351.
  • 13
    Mundy GR. Bisphosphonates as cancer drugs. Hosp. Pract. 1999; 34: 8194.
  • 14
    Thurlimann G. Bisphosphonates. In: Schlag PM, Senn H-J, ed. Clinical Oncology. Springer, Berlin, 1999; 113.
  • 15
    Theriault RL, Hortobagyi G. The evolving role of bisphos­phonates. Semin. Oncol. 2001; 28: 28490.
  • 16
    Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat. Rev. 2001; 27: 16576.
  • 17
    Berenson JR. New advances in the biology and treatment of myeloma bone disease. Semin. Hematol. 2001; 38: 1520.
  • 18
    Sillence DO. Disorders of bone density, volume and mineralisation. In: Rimoin DL, ed. Emory and Rimoin's Principles and Practice of Medical Genetics. Churchill Livingstone, London, 2002; 357406.
  • 19
    Zacharin M, Cuindy T. Osteoporosis pseudoglioma syndrome: Treatment of spinal osteoporosis with intravenous bisphos­phonates. J. Pediatr. 2000; 137: 41015.
  • 20
    Glorieux FH, Bishop N, Plotkin H, Chabot G, Lanoue G, Travers RT. Cyclic administration of pamidronate in children with severe osteogenesis imperfecta. N. Engl. J. Med. 1998; 339: 94752.
  • 21
    Plotkin H, Rauch F, Bishop N et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J. Clin. Endocrinol. Metab. 2000; 85: 184650.
  • 22
    Bembi B, Parma A, Bottega M et al. Intravenous pamidronate treatment in osteogenesis imperfecta. J. Pediatr. 1997; 131: 6225.
  • 23
    Hoekman K, Papapoulos S-E, Peters A-C, Bijvoiet O-L. Characteristics and bisphosphonate treatment of a patient with juvenile osteoporosis. J. Clin. Endocrinol. Metab. 1985; 61: 9526.
  • 24
    Shaw N, Boivin C, Crabtree N. Intravenous pamidronate in ­juvenile osteoporosis. Arch. Dis. Child. 2000; 83: 1435.
  • 25
    Lala R , Matarazzo P, Bertelloni S, Buzi F, Rignon F, De Sanctis C. Pamidronate treatment of bone fibrous dysplasia in nine children with McCune Albright syndrome. Acta Paediatr. 2000; 89: 18893.
  • 26
    Zacharin M, O'Sullivan M. Intravenous pamidronate treatment of polyostotic fibrous dysplasia associated with the McCune Albright syndrome. J. Pediatr. 2000; 137: 4039.
  • 27
    Buckmaster A, Rodda C, Cowell CT, Ogle G. The use of pamidronate in PTHrP associated hypercalcemia in infancy. J. Pediatr. Endocrinol. Metab. 1997; 10: 3014.
  • 28
    Lteif AN, Pennisi M, Barbi E, Pozzi R. Bisphosphonates for treatment of childhood hypercalcemia. Pediatrics 1998; 102: 99093.
  • 29
    Lepore L, Pennisi M, Barbi E, Pozzi R. Treatment and prevention of osteoporosis in juvenile chronic arthritis with disodium clodronate. Clin. Exp. Rheumatol. 1991; 9: 335.
  • 30
    Bassett C, Donath A, Macagno F, Preisig R , Fleisch H, Francis M. Bisphosphonates in the treatment of myositis ­ossificans. Lancet 1969; 2: 845.
  • 31
    Haworth CS, Selby P, Webb AK, Mawer EB, Adams JE, Freemont TJ. Severe bone pain after intravenous pamidronate in adult patients with cystic fibrosis. Lancet 1998; 352: 17534.
  • 32
    Haworth CS, Selby P, Webb AK, Adams JE, Freemont TJ. Oral corticosteroids and bone pain after pamidronate in adults with cystic fibrosis. Lancet 1999; 353: 18868.
  • 33
    Teramoto S, Matsuse T, Yasuyoshi O. Increased cytokines and pamidronate-induced bone pain in adults with cystic fibrosis. Lancet 1999; 353: 750.
  • 34
    Li C, Mori S, Li J et al. Long term effect of incandronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. J. Bone Miner. Res. 2001; 16: 42936.
  • 35
    Lions D, Delmas P, Meunier PJ. Long term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 1994; 343: 9534.
  • 36
    Rogers JG, Dorst J, Geho WB. Use and complications of high dose disodium etidronate therapy in fibrodysplasia ossificans ­progressiva. J. Pediatr. 1977; 91: 101214.
  • 37
    Adamson BB, Gallacher S, Byars J, Ralston SH, Boyle IT, Boyce BF. Mineralisation defects with pamidronate therapy for Paget's disease. Lancet 1993; 342: 145960.
  • 38
    Fleisch H. Bisphosphonates: mechanisms of action. Endocr. Rev. 1998; 19: 80100.
  • 39
    Little DG, Cornell M, Briody J, Cowell CT, Arbuckle S, Cooke-Yarborough C. Intravenous pamidronate reduces osteo­porosis and improves formation of the regenerate during distraction osteogenesis. A study in immature rabbits. J. Bone Joint Surg. Br. 2001; 83: 106974.